Epoprostenol
Orphan Drug Cold Chain RequiredFDA Approved
Description
Epoprostenol is a prostacyclin vasodilator used for severe pulmonary arterial hypertension. It requires continuous IV infusion and cold chain storage. The drug has been investigated for use in complex congenital cardiopulmonary malformations.
Indications & Therapeutic Use
Pulmonary arterial hypertension, congenital cardiopulmonary malformations
Linked Diseases:
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Epoprostenol
| Generic Name | Epoprostenol |
| Brands | 1 brand available |
| Active Ingredient | Epoprostenol sodium |
| Drug Class | Pulmonary arterial hypertension |
| Manufacturer | GlaxoSmithKline |
| Dosage Forms | IV infusion, 0.5mg and 1.5mg vials for reconstitution |
| Medical Code | B01AC09 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00000601 |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes